ClinicalTrials.gg
TerminatedNCT05140824Updated Apr 15, 2024

A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus

A Phase 1 interventional study of Placebo and TJ202 injection in Systemic Lupus Erythematosus (SLE), sponsored by TJ Biopharma Co., Ltd.. Terminated at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by TJ Biopharma Co., Ltd. · Phase 1, Interventional, and Treatment

Why this study was terminated
Company development strategy adjustment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Enrollment
241st of 245
1 · median 36
Started
2021
with 14 others
Phase 1
109 of 266
85 open now
Registered
61st of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 241st largest by enrollment of the 245 interventional ones that give a count, is one of 15 that started in 2021, is one of 109 in phase 1, and was the 61st registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients with Systemic Lupus Erythematosus

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)

Keywords

  • Evaluate the Safety, Tolerability
  • A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (subjects must meet all the following criteria for inclusion in this study):

Single Dose:

  1. Male or female, 18-65 years old (inclusive), weight of ≥ 45 kg.
  2. Definite diagnosis of systemic lupus erythematosus (see Annex 3. SLE Classification Criteria by SLICC 2012 for diagnostic criteria), and an SLE disease activity index (SLEDAI) score of \< 15 (see Annex 4. SLE Disease Activity Score [SLEDAI-2000] for scoring criteria) . A positive antinucleus antibody (ANA) test result.
  3. If a subject is receiving SLE treatment, a stable SLE regimen must be maintained up to the date of the first dose of study drug (the permitted medications and their maximum doses are as follows):

    • : prednisone 10 mg/day or other glucocorticoids with an equivalent dose. It should be stable for at least 4 weeks prior to receiving the first dose of study drug.
    • Other drugs alone or in combination with glucocorticoids include the following: azathioprine (maximum dose of 100 mg/day), methotrexate (maximum dose of 15 mg/week), mycophenolate mofetil (maximum dose of 1500 mg/day), tripterygium wilfordii polyglycosides (maximum dose of 60 mg/day), leflunomide (maximum dose of 20 mg/day), tacrolimus (maximum dose of 4 mg/day), ciclosporin (maximum dose of 100 mg/day). The above medications should be used for at least 12 weeks and stable for at least 4 weeks prior to receiving the first dose of study drug.
    • Hydroxychloroquine: The maximum allowable dose is 400 mg/day, and combination with the immunosuppressants listed above is allowed. It should be used for at least 12 weeks and the dose should be stable for at least 4 weeks prior to receiving the first dose of study drug.
  4. The subject is willing to participate in the study and voluntarily sign the ICF.
  5. Subjects of or subjects with a partner of childbearing potential must agree to use effective measures throughout the study (except oral estrogens, estrogenic vaginal ring, etc., refer to Annex 5. Contraceptive Measures, Definitions of Women of Childbearing Potential and Contraception Requirements for optional contraceptive methods).

    Multiple Doses: in addition to the single-dose inclusion criteria, subjects should meet the following criteria

  6. dsDNA antibody titer (ELISA) greater than or equal to 1.5 times the (ULN).

Exclusion Criteria (subjects who meet any of the following criteria will be excluded from the study):

  1. Central nervous system (CNS) diseases: active central nervous system lupus (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, or CNS vasculitis), visual disturbance, cranial neuropathy within 60 days prior to screening, with intervention required.
  2. Renal disorders: nephrotic syndrome (protein urine > 3.5 g/24 h) within 30 days prior to screening, or requiring protocol-prohibited medications (such as intravenous cyclophosphamide) for active nephritis, or requiring hemodialysis or high-dose glucocorticoids such as prednisone of ≥ 100 mg/day (or other glucocorticoids with equivalent doses).
  3. Cardiovascular disorders: history of acute myocardial infarction, or unstable angina, severe arrhythmia (multifocal frequent ventricular premature beats, ventricular tachycardia, ventricular fibrillation), etc. over the past six months; (NYHA) Class III-IV (see Annex 6. NYHA for details).
  4. Subjects with a known history of moderate or severe persistent asthma (assessed by the Asthma Severity Scale of the National Heart, Lung, and Blood Institute [NHLB]) within the past 5 years, or who currently have uncontrolled asthma (of any grade).
  5. Asthma and specific dermatitis, etc. requiring glucocorticoid-dependent therapy (except topical glucocorticoids).
  6. Infections, requiring treatment for acute or chronic infections, as follows:

    • Treatment with any inhibitory therapy currently for chronic infections (e.g., tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, zoster virus and atypical mycobacteriosis);
    • Hospitalization for an infection within 60 days prior to dosing;
    • Treatment with anti-infective drugs (antibacterials, antivirals, antifungals, or antiparasites) by parenteral administration (IV or IM) 60 days prior to dosing.
    • Subjects with mycobacterium tuberculosis, including those with a positive "T-cell spot test for tuberculosis infection (T-SPOT)" (latent tuberculosis infection: except those who have completed tuberculosis prophylaxis for 4 weeks before their first dose), or those with a positive imaging result.
  7. Subjects with positive results from any of the following tests: surface antigen (HBs Ag), hepatitis B core antibody (HBc Ab), virus antibody (HCV Ab), antibody (HIV Ab), or treponema pallidum antibody (TPPA). Patients who tested positive for hepatitis B core antibody (HBc Ab) but negative for HBV-DNA should be excluded.
  8. Hematological system diseases or hematology abnormalities: subjects with previous or current hematological system diseases (including but not limited to: myelofibrosis, anemia aplastic aregenerative, leukemia, lymphoma, etc.), hematology with \< 100 g/L, white blood cells \< 3.0 × 109/L, granulocytes \< 2.5 × 109/L, lymphocytes \< 0.8 × 109/L, or \< 100 × 109/L.
  9. Abnormal liver function: (AST) or alanine aminotransferase (ALT) or glutamyl transpeptidase (GGT) values > 2 times ULN; or total or alkaline phosphatase (ALP) values > 1.5 times ULN.
  10. Abnormal renal function: creatinine (Cr) or urea nitrogen (BUN) values > 1.5 times the upper limit of normal (ULN); pre-screening estimated (eGFR) ≤ 60 mL/min. Calculate eGFR values using the MDRD formula: eGFR (mL/min × 1.73 m2) = 175 × blood creatinine ([Scr (mg/dL)])-1.154 × age-0.203 × sex (M = 1, F = 0.742).
  11. Cancer: history of within the last 5 years.
  12. Transplant: history of major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell or bone marrow transplant.
  13. Female subjects with a positive serum pregnancy test or currently lactating.
  14. History of major surgery (craniotomy, thoracotomy, or laparotomy) or presence of unhealed wounds, ulcers, or fractures within 4 weeks prior to the first dose of study treatment.
  15. Targeted drug therapy: rituximab within 180 days before the first dose; any drug therapy targeting T-lymphocytes, B-lymphocytes, cytokines or receptors [e.g., belimumab, telitacicept, abatacept, etc.] within 90 days before the first dose; JAK inhibitors within 30 days before the first dose; other drugs for less than 5 half-lives.
  16. Subjects who have participated in any other clinical trials (including receiving investigational vaccines) or received treatment with invasive and investigational medical devices within 3 months before inclusion, or are being enrolled into an interventional and investigational study.
  17. Stable doses of anticoagulant or antiplatelet drugs used before randomization that exceeded regular doses or was increased within 7 days before dosing.
  18. Immunosuppressants:

    • Have received any of the following treatments within 90 days prior to screening: Intravenous immunoglobulin (IVIG);Use of high-dose glucocorticoids such as prednisone ≥ 100 mg/day;Plasma exchange, leukopheresis;Cyclophosphamide.
    • Use of immunomodulatory agents such as thymosin within 30 days prior to screening.
  19. Vaccination within 30 days prior to the first dose of study treatment.
  20. Use of traditional Chinese medicinal products or herbal preparations such as total glucosides of white paeony capsules, zhengqinfengtongning and colquhounia root tablets within 30 days prior to the first dose of study treatment.
  21. Drug abusers determined by medication history inquiries, including morphine, ketamine, tetrahydrocannabinolate, methamphetamine, dimethyldioxymethamphetamine and cocaine.
  22. Subjects who have consumed more than 14 units of alcohol/week (1 unit of alcohol = 360 mL of beer, 150 mL of wine, or 45 mL of liquor) within 3 months prior to screening, or who cannot abstain from alcohol during the trial, as determined by history inquiries.
  23. Other conditions: including laboratory abnormalities, history of any other disease (e.g., recent history of septicemia), unstable or uncontrolled acute or chronic conditions unrelated to SLE (e.g., acute pneumonia, pulmonary arterial hypertension, diabetic ketoacidosis, acute pancreatitis, etc.). In the opinion of the investigator, the above conditions may confound the study results or place the subject at an inappropriate risk. Thus, the subjects who experience the conditions above are not suitable for participation in this study.
  24. Subjects who are unsuitable for participation in this clinical study for any other reasons as determined by the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Placebo comparator
    Placebo

    0.9% sodium chloride solution

    Drug: Placebo

  • Experimental
    TJ202

    TJ202 injection

    Biological: TJ202 injection

Interventions

  • DrugPlacebo

    0.9% sodium chloride solution

  • BiologicalTJ202 injection

    TJ202 injection

06

What researchers measure

Primary outcomes

  1. Rate of Adverse Events

    Evaluate the rate of adverse events

    Time frame: 43 days post last dose for single dose

  2. Rate of Adverse Events

    Evaluate the rate of adverse events

    Time frame: 113 days post last dose for multi- dose

  3. Pharmacokinetic(PK) Parameters: Cmax

    Cmax

    Time frame: 43 days post last dose for single dose,

  4. Pharmacokinetic(PK) Parameters: Cmax

    Cmax

    Time frame: 113 days post last dose for multi- dose

  5. Pharmacokinetic(PK) Parameters: Tmax

    Tmax

    Time frame: 43 days post last dose for single dose,

  6. Pharmacokinetic(PK) Parameters: Tmax

    Tmax

    Time frame: 113 days post last dose for multi- dose

  7. Pharmacokinetic(PK) Parameters: AUC

    AUC0-tlast

    Time frame: 43 days post last dose for single dose,

  8. Pharmacokinetic(PK) Parameters: AUC

    AUC0-tlast

    Time frame: 113 days post last dose for multi- dose

07

Study locations

2 sites
  • The Second Affiliated Hosptial Zhejiang University School of Medicine
    Zhejiang, Hangzhou, China
  • Huashan Hospital affiliated to Fudan University
    Shanghai, Shanghai 200040, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Dec 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2021
First posted
Dec 1, 2021
StartActual
Dec 30, 2021
Primary completionActual
Dec 14, 2022
CompletionActual
Dec 14, 2022
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05140824
Lead sponsor
TJ Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Dec 30, 2021
Primary completion
Dec 14, 2022
Completion
Dec 14, 2022
Last update
Apr 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Felzartamab

Start the discussion